Omnia Biologics and Intradigm Sign Deal for Nanomedicine Manufacture
Omnia Biologics (Omnia) is a contract manufacturer focused on clinical trials material manufacture of innovative biopharmaceuticals. Intradigm is developing siRNA-derived therapeutics utilizing its proprietary nanomedicine technology and has led the advancement of siRNA from the test tube to a potent, tissue-targeted, systemically active therapeutic class of gene specific inhibitors. Intradigm was the first to demonstrate consistent and reproducible siRNA activity and efficacy in clinically relevant animal disease models through targeted formulations of siRNA for systemic administration.
“Omnia provides unique services for bridging pre-clinical and clinical manufacture. The breadth of their services is particularly important to small companies and those developing novel pharmaceuticals at pilot scale. We are very pleased to have their development assistance as we move toward the clinic.”
"Dr. Woodle and his team have an impressive track record of success in developing first in class drug delivery systems in oncology." Dr. Dale VanderPutten, CEO, Omnia Biologics, Inc. commented on the deal. "Their application of this expertise to siRNA at Intradigm is a huge step forward for making nanotechnology practical in medicine. Intradigm's technology has begun to transcend traditional notions of small molecules versus biologics by incorporating aspects of each. The advantages of this technology over current therapeutic regimes are enormous and we are overjoyed that Intradigm chose Omnia to assist them in this important work."
"Omnia provides unique services for bridging pre-clinical and clinical manufacture. The breadth of their services is particularly important to small companies and those developing novel pharmaceuticals at pilot scale. We are very pleased to have their development assistance as we move toward the clinic." commented Dr. Martin Woodle, CSO, Intradigm Corporation.
About Omnia Biologics: (www.omniabiologics.com)
Omnia offers services in the areas of process development, GMP manufacture, and fill-finish for preclinical and Phase I clinical programs for therapeutics that do not have effective or known manufacturing protocols. These include vaccines, autologous therapeutics, new gene therapeutic platforms, and stem cell technologies. The company seeks and has established relationships with both biopharmaceutical companies and academic investigators throughout the world.
About Intradigm: (www.intradigm.com)
Intradigm Corporation is a privately held Delaware corporation that is developing therapeutic products based on RNAi technology for cancer and other critical diseases. The Company is developing a portfolio of novel cancer therapeutics using its proprietary TargeTran(TM) technology for systemic targeted delivery of siRNA. Intradigm has a growing portfolio of novel targets for cancer therapeutics and associated candidate therapeutic agents including siRNA, antibodies, and small molecules. Intradigm's lead siRNA cancer therapeutic candidate, ICS-283, is in late pre-clinical development for solid tumors. Intradigm is located in the Association for Entrepreneurial Sciences Inc. facilities in Rockville, MD.